Modality
siRNA
MOA
KRASG12Ci
Target
PD-L1
Pathway
Epigenetic
FLCLLPsA
Development Pipeline
Preclinical
~Apr 2014
→ ~Jul 2015
Phase 1
~Oct 2015
→ ~Jan 2017
Phase 2
~Apr 2017
→ ~Jul 2018
Phase 3
~Oct 2018
→ ~Jan 2020
NDA/BLA
Apr 2020
→ Feb 2026
NDA/BLACurrent
NCT05963739
2,869 pts·PsA
2020-04→2026-02·Completed
2,869 total pts1 indication
Approved
CompletedCurrentUpcoming
Catalysts (1)
2026-02-092mo agoPh3 Readout· PsA
Trial Timeline
Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026
NDA/BLA
Complet…
Catalysts
Ph3 Readout
2026-02-09 · 2mo ago
PsA
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05963739 | NDA/BLA | PsA | Completed | 2869 | DAS28 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Lisolucimab | Novartis | Approved | CD20 | |
| Gozelemzoparlimab | Merck & Co | Phase 2 | FXIa | |
| ABB-7516 | AbbVie | Phase 3 | PD-L1 | |
| AZN-8478 | AstraZeneca | NDA/BLA | SHP2 | |
| Pexazasiran | Sanofi | Preclinical | FXIa | |
| Terasacituzumab | Novo Nordisk | NDA/BLA | IL-23 | |
| Olpatinib | GSK | Preclinical | PD-L1 | |
| BAY-3684 | Bayer | Approved | PD-L1 | |
| ALN-6288 | Alnylam | Approved | LAG-3 | |
| BMR-9762 | BioMarin | Phase 3 | Aβ |